Companies › 3D Medicines (Sichuan)
1 active drug program in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Envafolimab (KN035) Programmed cell death 1 ligand 1 binding agent | CD274 | Phase 3 | Non-small Cell Lung Cancer; Advanced Endometrial Cancer; Solid Tumor; Solid Tumors | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05112991 | Envafolimab (KN035) | Phase 2 | Advanced Endometrial Cancer | Oncology | Dec 2026 |
| NCT05024214 | Envafolimab (KN035) | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT03667170 | Envafolimab (KN035) | Phase 2 | Solid Tumor | Oncology | Dec 2026 |
| NCT04891198 | Envafolimab (KN035) | Phase 2 | Solid Tumor | Oncology | Aug 2027 |
| NCT06123754 | Envafolimab (KN035) | Phase 3 | Non-small Cell Lung Cancer | Oncology | Dec 2027 |
AstraZeneca Pfizer IO Biotech ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical Shanghai Henlius Biotech
ImmuneOncia Therapeutics PharmaEssentia Protagonist Therapeutics Greenwich LifeSciences Jiangsu Healthy Life Innovation Medical Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.